1 The objective of this study was to investigate the efficacy of home-medicated non-steroidal anti-inflammatory (NSAID) analgesics, using an electronic patient diary. Single doses of ketoprofen 25 mg and ketoprofen 50 mg were compared with ibuprofen 200 mg and placebo in the treatment of a single occasion of episodic tension-type headache, using a double-blind, randomized, parallel group design. 2 A total of 166 patients with headache compatible with episodic tension-type headache and no refractory headaches or contraindications to NSAIDs were contacted by advertisements and selected by questionnaires. Patients performed the study at home, using an electronic diary for headache assessment, with a form to allow comments and corrections. Visual analogue scales (VAS 10 cm) of headache severity, five-item headache relief rating (HRR) scales, and time of intake of 'escape' analgesics were scored regularly, for 4 h following intake of trial medication. 3 VAS-scores (n=1407) and HRRs (n=452) were returned by 159 patients. Of these scores, 1.5% were inadvertedly omitted from the electronic diary or modified on the comment forms. 4 Headache ( VAS and HRR) improved more with all three NSAIDs than with placebo, although the effect of ibuprofen was significant for HRR only. After 2 and 4 h respectively, the reduction in VAS-ratios was 17 and 19% with placebo, 18 and 53% with ibuprofen 200 mg, 41 and 61% with ketoprofen 25 mg, and 47 and 59% with ketoprofen 50 mg. After 4 h, headache improved strongly ( highest HRR) in 18% of patients on placebo, 39% on ibuprofen 200 mg, 62% on ketoprofen 25 mg, and 55% on ketoprofen 50 mg. Headache disappeared completely ( VAS-score=0) in one patient (3%) with placebo (after 180 min), 10% with ibuprofen 200 mg (average 211 min), 18% with ketoprofen 25 mg (159 min), and 28% with ketoprofen 50 mg ( 146 min). 5 The effects of ketoprofen 50 mg were more pronounced than those of ibuprofen 200 mg, which seemed to start later. Ketoprofen 25 mg and 50 mg were very similar, suggesting a maximal effect of the lower dose. Mild to moderate adverse events were reported by 9% of the patients, half of which occurred with ketoprofen 50 mg. Treatment of headache with ketoprofen can start with 25 mg, and possibly less. 6 Although a direct comparative study would be necessary to determine the relative benefits of the novel electronic patient diaries over traditional paperand-pencil methods, this study has shown the usefulness of this newer technique to detect differences in efficacy between low doses of analgesics under ambulant conditions, with very limited loss of data. Electronic patient In the 2 months prior to the participation, subjects were required to have suffered from between four and twentyfor headache in several countries. Ketoprofen has recently also been registered for self-medication [17 ] , four occasions of headache of at least moderate severity, usually lasting at least 3 h and usually responsive to but its efficacy in tension-type headache is undetermined.
The assessment of analgesics in headache poses several self-medicated analgesics. Patients with criteria conforming to unspecified tension-type headache (IHS 2.3) difficulties [18 ] . Although trial procedures can be intensively monitored at research institutions, this entails that otherwise satisfied the study criteria were also included, if they usually responded satisfactorily to a self-selection by the patient of the moment to go to the institute with headache. This decision will be analgesics. Patients with features suggestive of other (concomitant) headache types were excluded, notably influenced by matters of convenience and by pain intensity, which in turn can be altered during transpormigraine (IHS 1), chronic tension-type headache (IHS 2.2) or cluster-type headaches (IHS 3 ). Subjects tation to the institution, and by the unusual trial circumstances. Hence, the ingestion of analgesics in with health hazards for the use of NSAIDs were also excluded. All subjects participated after full written in-patient studies may not be truly representative of the spontaneous intake of pain-killers for 'ordinary' headinformed consent. The study was approved by the Medical Ethics Committee of Leiden University aches. Ambulant studies require full cooperation by the patient, which may be less reliable particularly when Hospital. headache is severe. The use of an electronic patient diary may improve the reliability of home-collected data, allowing a more precise evaluation of drugs in Study design and medication ambulant situations, such as during chronic treatment [ 19] . The present study used electronic diaries to homeThis study was a single dose, double-blind, randomized, parallel group, placebo-controlled efficacy study of monitor the efficacy of ketoprofen (25 mg and 50 mg), compared with ibuprofen 200 mg and placebo, during ketoprofen 25 mg, ketoprofen 50 mg and ibuprofen 200 mg, in the treatment of a single headache occasion, self-medication of a single occasion of episodic tensiontype headache.
home-monitored with an electronic patient diary. Subjects were allowed to use their personal analgesic medication as an 'escape', if headache relief was insufficient after at least 2 h following ingestion of trial medication. Methods
Subjects
Electronic patient diary Volunteers of at least 18 years of age, with regular headaches of at least four times a month, but no more After selection, patients were invited to the institute in groups of 2-10 subjects, for thorough instructions than three times a week and no migraine, were approached by advertisements in regional newspapers about the study design, and to practice with the electronic patient diary. The electronic patient diary and on local cable television. Responders were provided (MiniDoc AB, Uppsala, Sweden) is specifically designed Statistical analysis for out-patient clinical trials [19 ] . The apparatus is essentially a portable computer with a large LCD-
The number of subjects in each treatment group (forty) was based on comparable parallel-group trials of screen and four push-buttons, which are preprogrammed according to the study protocol. The arylpropionic acid derivatives in episodic tension-type headache, where 35-50 patients per treatment group main features of the programme were 10 cm visual analogue scales (VAS) of headache intensity and five sufficed to detect a significant analgesic effect [12] [13] [14] [15] . Studies of ketoprofen 25 mg in pain other than headache item headache relief ratings (HRR). In addition, the ingestion of personal ('escape') analgesic medication showed significant effects in 14-50 patients per group [2] [3] [4] [5] [6] [7] . Statistical analyses were performed on the as per and its time could be indicated, either upon request at scheduled timepoints, or spontaneously in between.
protocol population. VAS headache scores and HRRscores were analysed by a procedure analogous to a The different steps of the programme were evoked in a scheduled order, by means of an alarm with fixed repeated measures ANOVA, adequately accounting for missing data (SAS PROC MIXED, SAS for Windows time intervals. Previously entered responses were not displayed. Any omitted information was requested V6.07, SAS Institute Inc., Cary, NC). The study was designed to produce a final VAS-or Headache Relief again at the next scheduled time point. The programme could not be interrupted after the start, except to score prior to ingestion of 'escape' medication (if applicable), but all datapoints expected thereafter were indicate the ingestion of 'escape' analgesics. The entered data could not be changed afterwards. Since there was considered missing. VAS-scores were analysed as raw scores (9 in total) from 0 to 240 min. VAS-scores were no opportunity for corrections, patients were provided with a comment form that contained important study significantly related to the values at baseline, shown by covariance analysis (P<0.0001). Hence, VAS-scores guidelines and visual analogue lines, giving the opportunity to change data that were considered to were also analysed as the ratio of scores relative to the pre-value (t=0 min) (8 in total) from 15 to 240 min. have been incorrectly entered into the diary. Patients were clearly instructed that only obvious errors should Pairwise differences between treatments were assessed using contrasts on average treatment effects. The be corrected immediately after these were made.
following categorical variables were analysed using Fisher's exact test: intake of escape medication, intake of escape medication immediately after 120 min, headache free status at 240 min (VAS=0), strong headache Headache assessment relief (HRR=4 ) at 240 min, presence of unspecified tension-type headache (IHS 2.3), and adverse events. Subjects were instructed to switch on the electronic patient diary, during the first occasion of episodic Contrasts between treatments were only examined in case of overall significant differences (set at 5%). tension-type headache to occur within the first month after the screening period, when the headache reached Significance levels for contrasts between groups were set at 1% to account for multiple comparisons. Results are at least moderate severity. The diary programme initially checked whether the headache was at least reported as averages with 99% confidence intervals, or with P values in case of Fisher's exact test. moderately severe, indicated by VAS-score of 25% or more of the maximal headache level. If so, the patient was instructed to take the trial medication. The diary then prompted for entry of the next VAS-score with loud bleeps at 15, 30, 45, 60, 90, 120, 180 and 240 min.
Results In addition, a five-item Headache Relief Rating-(HRR)-score (0 strong worsening-1 slight worseningSubjects and data 2 no change-3 slight improvement-4 strong improvement) was obtained at 120, 180 and 240 min. Two A total of 303 individuals responded to the advertisements. Two hundred and forty-eight questionnaires were hours or more after intake of the test drug, the patients were allowed to take their own analgesic medication. If returned. Eighty subjects were rejected: 48 for suspected (concomitant) migraine; 11 for too frequent or chronic so, they were instructed to switch on the electronic diary, which then inquired about the time of ingestion headache; 6 for absent relief from self-medicated analgesics; 4 for contra-indications to the use of NSAIDs; 2 of 'escape' analgesics, and the VAS-and HRR-scores immediately before ingestion. The programme also for intercurrent illness; 1 for suspected inability to operate the electronic diary; and 8 for mixed reasons. inquired at 180 and 240 min about the intermediary use of such analgesics. The study was terminated after
Of the 168 eligible subjects, 140 patients matched the criteria for episodic tension-type headache (IHS 2.1.1 or 'escape' analgesics was taken, or after 4 h. When the trial material was returned, patients were asked about 2.1.2) and 28 for unspecified tension type-headache (IHS 2.3). Two subjects refused further participation; 41 their experience with the diary programme, the effect of trial medication, the use of 'escape' analgesics, and received placebo, 42 ibuprofen 200 mg, 41 ketoprofen 25 mg, and 42 ketoprofen 50 mg. Of the 166 participants, adverse events. The data retrieved from the diary and the corrections on the comment form were compared three subjects took trial medication without entering any data into the electronic diary, and four subjects with the overview provided by the patient. Clear discrepancies were investigated.
withdrew consent and returned the unused trial material.
Of the remaining 159 subjects who returned evaluable data, 39 patients received placebo, 40 ibuprofen 200 mg, 39 ketoprofen 25 mg, and 40 ketoprofen 50 mg. Only minor deviations from protocol were encountered. Eleven subjects made changes on the comment form, which were analysed instead of the data originally entered into the electronic diary. In this way, 10/1407 VAS-scores (0.7%) and 9/452 HRR-scores (2%) were corrected; five HRR-scores (1.1%) and three VAS-score (0.2%) were lost. Overall, 1.5% of the analysed data were lost or different from the original diary entries. There were no differences in demographic data or headache characteristics at baseline (Table 1 ) . More women participated in the study than men (109 vs 50 ). development of the raw VAS-scores over the entire 4 h period is shown in Table 2 . Both ketoprofen doses differed significantly from placebo, but the differences (1, 37%)). The average difference between ibuprofen and placebo was not statistically significant (3% (−2, 34%)). between the three active treatment groups were not statistically significant. The treatment effects became Only one patient from the placebo group (3%) became free of headache (defined as a VAS-score of 0), more pronounced, if the baseline VAS-scores were taken into account. Figure 1 shows the VAS-scores as ratios after 3 h. In the ibuprofen 200 mg group, four patients (10%) became headache-free after an average of 211 min of the pre-treatment value. Ketoprofen 25 mg and 50 mg reduced VAS-ratios significantly more than placebo (range 181-242 min), compared with seven patients (18%) in the ketoprofen 25 mg group (159 (average difference with placebo (99% confidence interval) over 4 h: 20% (1, 38%) and 22% (4, 41%), (60-242) min), and 11 (28%) in the ketoprofen 50 mg group (146 (30-241) min). More patients lost their respectively). The higher dose was also significantly more effective than ibuprofen 200 mg (difference 19% headache with ketoprofen 50 mg than with placebo (P=0.003). There were non-significant differences between placebo and ketoprofen 25 mg (P=0.056) and between ketoprofen 50 mg and ibuprofen 200 mg (P=0.049).
Headache relief ratings The average HRR-scores are shown in Figure 2 . Table 3 shows the differences between the four treatment groups. All NSAIDs gave significantly more pain relief than placebo. After 4 h, there was a strong improvement of headache (maximum HRR-score of 4 ) in seven patients (18%) on placebo, 16 (39%) on ibuprofen 200 mg, 24 (62%) on ketoprofen 25 mg, and 22 (55%) on ketoprofen 50 mg. Strong improvement Intake of 'escape' analgesics Figure 3 shows the numbers of patients resorting to 'escape' analgesics, and the Adverse events time of intake. Six patients on placebo (15%) used 'escape' medication immediately after this was allowed, Fourteen adverse events were reported. Seven occurred as opposed to one patient on ibuprofen 200 mg (2%) during treatment with ketoprofen 50 mg: two cases of and none on either dose of ketoprofen. Immediate resort mild gastointestinal discomfort, three of restlessness, one to 'escape' analgesics occurred (non-significantly) more of mild itching, and one case of moderate angioneurotic often during treatment with placebo than with either oedema responding to oral anti-histamine treatment. ketoprofen 25 mg (P=0.025), ketoprofen 50 mg (P= Adverse events did not occur significantly more often 0.012) or ibuprofen 200 mg (P=0.054).
(P>0.15) with ketoprofen 50 mg than with the other treatments (two with ketoprofen 25 mg group, three with ibuprofen 200 mg and two with placebo; mostly mild to moderate self-limiting gastrointestinal complaints or 'unusual' headache).
Discussion
The present study was designed to approach the situation where an 'over-the-counter' analgesic is occasionally taken for 'ordinary' headache. Both the selection of patients and the methods of evaluation were adapted to this every-day situation. Subjects were recruited by advertisement through local media, rather than through general practitioners, neurologists or improve the quality of the assessments. Data were not displayed and could not be changed after entry into the could indicate that ketoprofen has a 'ceiling' effect at about 25 mg in this type of pain, similar to post partum diary, to prevent post-hoc entrance or modification and to minimise carry-over effects from previous scores.
pain [5, 6] . In other pain models, however, ketoprofen 100 mg was more effective than 25 mg [3, 6, 7 ]. SelfPatients were thoroughly instructed, and a patient information-and correction form was provided with the medication for ordinary headache can be started at 25 mg or possibly less, considering that half of all electronic diary. Although this to some extent foils the essence of electronic patient diaries, many patients adverse events occurred with ketoprofen 50 mg. The present study showed the practicality of electronic wanted the opportunity to make remarks or modifications during the trial, although only 19 of 159 subjects diaries in the home-monitoring of 'over-the-counter' drugs. They can be an important new attribute in the actually used it. Thus, no more than 1.5% of the data were lost or modified. It is therefore very unlikely that development of self-medicated agents. an analysis of the unaltered electronic diary entries would have yielded different results. This suggests that
The Headache and Health Questionnaire was developed and it is unnecessary to backup electronic patient diaries kindly provided by M. D. Ferrari, and Ms W. H. Visser.
with paper-and-pencil methods. The large majority of the patients had no difficulties with the use of the electronic patient diary, and there generally seemed to References be a good agreement between the entered data and the overall patient assessment. Furthermore, this study paper-and-pencil methods cannot be determined from
